In CHIRACIC, adrenalectomy improved home-blood-pressure normotension with less medication versus conservative management in unilateral mild autonomous cortisol secretion-associated hypertension.
In ACROINNOVA 1, monthly self-injected CAM2029 maintained IGF-1 control in 72.2% of adults with controlled acromegaly versus 37.5% on placebo withdrawal.
In STEP UP, semaglutide 7.2 mg reduced body weight by 18.7% versus 3.9% with placebo and outperformed semaglutide 2.4 mg in adults with obesity without diabetes.
In an open-label Graves disease RCT, methotrexate 10 mg weekly added to methimazole increased treatment withdrawal at 18 months, but remains investigational.
In gestational diabetes requiring medication, metformin-first oral therapy with glyburide rescue did not prove noninferior to insulin for preventing large-for-gestational-age birth.
In early postmenopausal women aged 50 to 60 years, zoledronate at baseline and 5 years reduced 10-year morphometric vertebral fractures from 11.1% to 6.3%.
In overweight or obese adults with early type 2 diabetes, dapagliflozin added to calorie restriction increased 12-month remission from 28% to 44%.
In the IoN non-inferiority RCT, omitting postoperative radioiodine after total thyroidectomy produced 5-year recurrence-free survival of 97.9% versus 96.3% with ablation in selected low-risk thyroid cancer.
In REDEFINE 1, once-weekly cagrilintide-semaglutide produced 20.4% mean weight loss at 68 weeks versus 3.0% with placebo in adults with overweight or obesity without diabetes.
In insulin-treated type 2 diabetes, automated insulin delivery reduced HbA1c by an adjusted 0.6 percentage points and increased time in range by 14 points versus CGM with usual insulin delivery.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
